Short-term effect of amantadine sulphate on motor performance and reaction time in patients with idiopathic Parkinson's disease

Journal of Neural Transmission

Volumn 106, Issue 7-8, 1999, Pages 711-724

  Pinter, M M ^a   Birk, M ^a   Helscher, R J ^a   Binder, H ^a  

^a Neurol Hosp Maria Theresien S   (Austria)

Author keywords

Amantadine sulphate; Motor performance; Parkinson's disease; Reaction time

Indexed keywords

AMANTADINE; ANTIPARKINSON AGENT; BROMAZEPAM; HOFCOMANT; LEVODOPA; PERGOLIDE; SELEGILINE; UNCLASSIFIED DRUG;

ACCURACY; ADULT; AGED; ARM MOVEMENT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COGNITION; DISEASE SEVERITY; DRUG EFFICACY; FEMALE; FOLLOW UP; HAND MOVEMENT; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; MOTOR PERFORMANCE; PARKINSON DISEASE; PRIORITY JOURNAL; RATING SCALE; REACTION TIME; RESPONSE TIME; VELOCITY;

ADULT; AGED; AGED, 80 AND OVER; AMANTADINE; ANTIPARKINSON AGENTS; COGNITION; FEMALE; HUMANS; INJECTIONS, INTRAVENOUS; MALE; MIDDLE AGED; MOTOR SKILLS; PARKINSON DISEASE; PROSPECTIVE STUDIES; REACTION TIME;

EID: 0032813973     PISSN: 03009564     EISSN: None     Source Type: Journal    
DOI: 10.1007/s007020050191     Document Type: Article

References (57)

1. Aziz TZ, Peggs D, Argarwal E, Sambrook MA, Crossmann AR (1992) Subthalamic nucleotomy alleviates parkinsionism in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-exposed primates. Br J Neurosurg 6: 575-582
2. Bauer RB, McHenry JT (1974) Comparison of amantadine, placebo, and levodopa in Parkinson's disease. Neurology 24: 715-720
3. Benazzouz A, Gross C, Feger J, et al (1993) Reversal of rigidity and improvement in motor performance by subthalamic high-frequency stimulation in MPTP-treated monkeys. Eur J Neurosci 5: 382-389
4. Benazzouz A, Boraud T, Feger J, et al (1996) Alleviation of experimental hemiparkinsonism by high-frequency stimulation of the subthalamic nucleus in primates: a comparison with L-dopa treatment. Mov Disord 11(6): 627-632
5. Benabid AL, Pollak P, Gross C, et al (1994) Acute and long-term effects of subthalamic nucleus stimulation in Parkinson's disease. Stereotact Funct Neurosurg 62: 76-84
6. Bloxham CA, Mindel TA, Frith CD (1984) Initiation and execution of predictable and unpredictable movements in Parkinson's disease. Brain 107: 371-384
7. Bloxham CA, Dick DJ, Moore M (1987) Reaction times and attention in Parkinson's disease. J Neurol Neurosurg Psychiatry 50: 1178-1183
8. Brenner M, Haass A, Jacobi P, Schimrigk K (1989) Amantadine sulphate in treating Parkinson's disease: clinical effects, psychometric tests and serum concentrations. J Neurol 236: 153-156
9. Brown RG, Marsden CD (1986) Visuospatial function in Parkinson's disease. Brain 109: 897-1002
10. Büttner T, Kuhn W, Müller T, Patzold T, Przuntek H (1995) Color vision in Parkinson's disease: missing influence of amantadine sulphate. Clin Neuropharmacol 18: 458-463
11. Butzer JF, Silver DE, Sahs AL (1975) Amantadine in Parkinson's disease. Neurology 25: 603-606
12. Canavan AGM, Passingham RE, Marsden CD, Quinn N, Wyke M, Polkey CE (1989) The performance on learing tasks of patients in the early stages of Parkinsonian disease. Neuropsychologica 27: 141-156
13. Chierichetti SM, Ferrari P, Sala P, Vibelli C, Pietrzykowski A (1977) Effect of amantadine on mental status of elderly patients: a double blind comparison with placebo. Curr Ther Res 22: 158-165
14. Cooper JA, Sagar HJ, Jordan N, Harvey NS, Sullivan EV (1991) Cognitive impairment in early, untreated Parkinson's disease and its relationship to motor disability. Brain 114: 2095-2122
15. Evarts EV,Taravainen H, Calne DB (1981) Reaction times in Parkinson's disease. Brain 104: 167-186
16. Fahn S, Elton RL and Members of the UPDRS Development Committee (1987) Unified Parkinson's disease rating scale. In: Fahn S, Marsden CDE, Calne D, Goldstein M (eds) Recent developments in Parkinson's disease, 2. Mac Millian Healthcare Information, Florham Park NJ, pp 153-163
17. Fieschi C, Nardini M, Casacchia M, Tedone ME, Robotti E (1970) Amantadine for Parkinson's disease (letter). Lancet: 945-946
18. Gibb WRG, Lees AJ (1988) The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease. J Neurol Neurosurg Psychiatry 51: 745-752
19. Giotti F, Carella F, Grassi MP, Soliverri P, Marano R, Caraceni T (1986) Motor and cognitive performance of Parkinsonsian patients in the on and off phases of the disease. J Neurol Neurosurg Psychiatry 49: 657-660
20. Goldenberg G (1990) Performance of concurrent non-motor tasks in Parkinson's disease. J Neurol 237: 191-196
21. Gerlak RP, Clark R, Stump JM, Vernier VG (1970) Amantadine - dopamine interaction: possible mode of action in Parkinsonism. Science 169: 203-204
22. Greulich W, Fenger E (1995) Amantadine in Parkinson's disease: pro and contra. J Neural Transm [Suppl] 46: 415-421
23. Helscher RJ, Pinter MM (1992) Speed and power of higher cerebral functions in parkinsonian patients. J Neural Transm [P-D Sect] 5: 35-44
24. Helscher RJ, Pinter MM, Binder HK (1993) Cognivision - A software package for identification of neuropsychological deficits and rehabilitation. XVth World Congress of Neurology, Vancouver, Canada, Abstract. Can J Neurol Sci 20(4): 170
25. Horne DJ (1971) Performance on delayed response tasks by patients with Parkinsonism. J Neurol Neurosurg Psychiatry 34: 192-194
26. Hunter KR, Stern GM, Laurence DR, Armitage P (1970) Amantadine in Parkinsonism. Lancet i: 1127-1129
27. Jahanshahi M, Brown RG, Marsden CD (1992) The effect of withdrawal of dopaminergic medication on simple and choice reaction time and the use of advance information in Parkinson's disease. J Neurol Neurosurg Psychiatry 55: 1168-1176
28. Jahanshahi M, Brown RG, Marsden CD (1993) A comparative study of simple and choice reaction time in Parkinson's, Huntington's and cerebellar disease. J Neurol Neurosurg Psychiatry 56: 1169-1177
29. Jones DL, Phillips JG,Bradshaw JL, Iansek R, Bradshaw JA (1993) Coding of movement direction and amplitude in Parkinson's disease: are they differentially impaired (or unimportant)? J Neurol Neurosurg Psychiatry 56: 419-422
30. Klockgether TH, Löschmann PA, Wüllner U (1994) New medical and surgical treatments for Parkinson:s disease. Curr Opin Neurol 7: 346-352
31. Koller W (1986) Pharmacologie treatment of Parkinsonian tremor. Arch Neurol 43: 126-127
32. Lees AJ (1989) Neuropsychologische Störungen beim M. Parkinson. Nervenarzt 60: 71-79
33. Limousin P, Pollak P, Benazzouz A, et al (1995) Effect on parkinsonian signs and symptoms of bilateral subthalamic nucleus stimulation. Lancet 354: 91-95
34. Lindvall O, Rehncrona S, Brundin P, et al (1989) Human fetal dopaminc neurons grafted into the striatum in two patients with severe Parkinson's disease. A detailed account of methodology and a 6-month follow-up. Arch Neurol 46: 615-631
35. Mann DC, Pearce LA, Waterbury LD (1971) Amantadine for Parkinson's disease. Neurology 21: 958-962
36. Marsden CD (1984) Function of the basal ganglia as revealed by cognitive and motor disorders in Parkinson's disease. Can J Neurol Sci 11: 129-135
37. Mazzucchi A, Sinforiani E, Ludovico L, Turla M, Pacchetti C, Brianti R, Parma M, Nappi G (1993) Reaction time responses in parkinsonian and hemiparkinsonian patients. Mov Disord 8: 13-18
38. Montgomery ED, Nuessen J (1990) The movement speed/accuracy operator of Parkinson's disease. Neurology 40: 269-272
39. Montgomery EB, Gorman DS, Nuessen J (1991) Motor initiation versus execution in normal and Parkinson's disease subjects. Neurology 41: 1469-1475
40. Montgomery EB, Nuessen J, Gorman DS (1991) Reaction time and movement velocity abnormalities in Parkinson's disease under different task conditions. Neurology 41: 1476-1481
41. Muschard F, Völler GW (1973) Efficacy of amantadine sulphate as an infusion solution in the treatment of Parkinson's disease. Med Welt 5
42. Owen AM, Roberts AC, Hodges JR, Summers BA, Polkey CE, Robbins TW (1973) Contrasting mechanisms of impaired attentional set-shifting in patients with frontal lobe damage or Parkinson's disease. Brain 116: 1159-1175
43. Parkes JD, Curzon G, Knott PJ, Tattersall R, Baxter RCH, Knill - Jones RP, Marsden CD, Vollum D (1971) Treatment of Parkinson's disease with amantadine and levodopa. Lancet i: 1083-1086
44. Parkes JD, Baxter RC, Marsden CD, Rees JE (1974) Comparative trial of benzhexol, amantadine, and levodopa in the treatment of Parkinson's disease. J Neurol Neurosurg Psychiatry 37: 422-426
45. Phillips JG, Martin KE, Bradshaw JL, Iansek R (1994) Could bradykinesia in Parkinson's disease simply be compensation? J Neurol 241: 439-447
46. Pinter MM, Helscher RJ, Nasel ChOJ, Riedl E, Schnaberth G (1991) Quantification of motor deficit in Parkinson's disease with a motor performance test series. J Neural Transm [P-D Sect] 4: 131-141
47. Pullman SL, Watts RL, Juncos JL, Chase TN, Sanes JN (1988) Dopaminergic effects on simple and choice reaction time performance in Parkinson's disease. Neurology 38: 249-254
48. Pullman SL, Watts RL, Juncos JL, Sanes JN (1990) Movement amplitude choice reaction time performance in Parkinson's disease may be independent of dopaminergic status. J Neurol Neurosurg Psychiatry 53: 279-283
49. Rafal RD, Winhoff AW, Friedman JH, Bernstein E (1987) Programming and execution of sequential movements in Parkinson's disease. J Neurol Neurosurg Psychiatry 50: 1267-1273
50. Rafal RD, Friedmann JH, Lannon MC (1989) Preparation of manual movements in hemiparkinsonism. J Neurol Neurosurg Psychiatry 52: 399-402
51. Sheridan MR, Flowers KA, Hurrell J (1987) Programming and execution of movements in Parkinson's disease. Brain 100: 1247-1271
52. Starkstein S, Esteguy M, Berthier ML, Garcia H, Leiguarda R (1989) Evoked potentials, reaction time and cognitive performance in on and off phases of Parkinson's disease. J Neurol Neurosurg Psychiatry 52: 338-340
53. Sturm W, Büssing A (1985) Ergänzende Nominierungsdaten und T-Test-Reliabilitätskoeffizienten zur Motorischen Leistungsserie (MLS) nach Schoppe. Diagnostica 3: 234-245
54. Turski L, Bressler K, Rettig KJ, Löschmann PA, Wachtel H (1991) Protection of substantia nigra from MPP+ neurotoxicity by N-Methyl-D-aspartate antagonists. Nature 349: 414-418
55. Uitti RJ, Rajput AH, Ahlskog JE, Offord KP, Schroeder DR, Ho MM, Prasad M, Rajput A, Basran P (1996) Amantadine treatment is an independent predictor of improved survival in Parkinson's disease. Neurology 6: 1551-1556
56. Von Voigtlander RF, Moore KE (1971) Dopamine: release from the brain in vivo by amantadine. Science 74: 408-410
57. Wichmann T, Bergmann H, DeLong MR (1994) The primate subthalamic nucleus. III. Changes in motor behavior and neuronal activity in the internal pallidum induced by subthalamic inactivation in the MPTP model of parkinsonism. J Neurophysiol 72(2): 521-530